Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0294 • ACR Convergence 2023
Tofacitinib Treatment in Rheumatoid Arthritis Is Associated with Increased Lower Limb Muscle Volume: The Rheumatoid Arthritis and Muscle (RAMUS) Study
Joshua L Bennett¹, Kieren G Hollingsworth², Arthur Pratt³, Maha Egail³, Catherine Feeney⁴, Valeria Di Leo⁴, Robert W Taylor⁴, Richard Dodds⁵, Amy E Anderson³, Avan Aihie Sayer⁵ and John Isaacs⁶, ¹Immunity and Inflammation Theme, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle upon Tyne, United Kingdom, ²Innovation Methodology and Application Theme, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom, ³Immunity and Inflammation Theme, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁵AGE Research Group, NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals NHS Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ⁶Translational and Clinical Research Institute, Newcastle University and Musculoskeletal Unit, Newcastle Hospitals, Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
Background/Purpose: Approximately 1 in 4 people with RA have sarcopenia, defined as generalised loss of skeletal muscle (SKM) strength and mass, resulting in an increased…
Abstract Number: 0390 • ACR Convergence 2023
Statins Influence the Relationship Between ATP-binding Cassette Transporter A1 (ABCA1)-mediated Cholesterol Efflux and Coronary Atherosclerosis in Rheumatoid Arthritis
George Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², Elizabeth Hernandez³, Maria Pia Adorni⁴, Francesca Zimetti², Matthew Budoff¹ and Nicoletta Ronda², ¹Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Department of Food and Drug, Parma, Italy, ³The Lundquist Institute, Torrance, CA, ⁴Department of Medicine and Surgery, Unit of Neuroscience, University of Parma, Parma, Italy
Background/Purpose: Cholesterol efflux capacity (CEC) is the main antiatherogenic function of high-density lipoprotein (HDL). ATP-binding-cassette A1 (ABCA1) membrane transporter initiates cholesterol export from arterial macrophages…
Abstract Number: 0407 • ACR Convergence 2023
Meteorological Conditions Contribute to the Joint Ultrasound Findings in Patients with Rheumatoid Arthritis: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort Study
Masataka Umeda¹, Yushiro Endo², Tohru Michitsuji³, Ayako Nishino³, Shin-ya Kawashiri³, Shinpei Morimoto⁴, Masahiko Tuboi⁵, Naoki Matsuoka⁵, Keita Fujikawa⁶, Akinari Mizokami⁷, Yujiro Arinobu⁸, Tomomi Tsuru⁹, Hirokazu Takaoka¹⁰, Tamami Yoshitama¹¹, Tomoyuki Asano¹², Jun Ishizaki¹³ and Atsushi Kawakami¹⁴, ¹Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Medical Sciences, Nagasaki, Japan, ⁴Innovation Platform & Office for Precision Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ⁵Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, ⁶Japan Community Healthcare Organization, Isahaya General Hospital, Isahaya, Japan, ⁷Isahaya General Hospital, Isahaya, Japan, ⁸Department of Clinical Immunology and Rheumatology, Kyushu University Hospital, Fukuoka, Japan, ⁹Department of Rheumatology, Med.Co. LTA PS Clinic, Fukuoka, Japan, ¹⁰Section of Internal Medicine and Rheumatology, Kumamoto Shinto General Hospital, Kumamoto, Japan, ¹¹Yoshitama Clinic for Rheumatic Diseases, Kirishima, Japan, ¹²Fukushima Medical University, Fukushima, Japan, ¹³Department of Hematology, Clinical Immunology and Infectious Diseases Ehime University Graduate School of Medicine, Toon, Japan, ¹⁴Nagasaki University, Nagasaki, Japan
Background/Purpose: Various environmental factors are involved in the pathogenesis of rheumatoid arthritis (RA), and meteorological conditions such as temperature and atmospheric pressure have also been…
Abstract Number: 0424 • ACR Convergence 2023
Real-World Effectiveness of Upadacitinib in Patients with Moderate/Severe Rheumatoid Arthritis: 6-Month Data from the Observational UPHOLD Study
Andrew Östör¹, Eugen Feist², Prodromos Sidiropoulos³, Jérôme Avouac⁴, Martin Rebella⁵, Rajaie Namas⁶, Bruno Frediani⁷, Song-Chou Hsieh⁸, Tianming Gao⁹, Nasser Khan¹⁰, Sander Strengholt¹¹, Ivan Lagunes-Galindo¹⁰ and Susan Attar¹², ¹Monash University & Emeritus Research; Australian National University, Melbourne, Australia, ²Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, ³Faculty of Medicine, University of Crete, Heraklion, Greece, ⁴Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France, ⁵Departamento de Medicina, Facultad de Medicina, Universidad de la República; Unidad de Enfermedades Autoinmunes Sistémicas, MUCAM, Montevideo, Uruguay, ⁶Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ⁷Santa Maria alle Scotte General Hospital, Siena, Italy, ⁸National Taiwan University Hospital, Taipei, Taiwan, ⁹AbbVie, Inc., North Chicago, IL, ¹⁰Pharmacovigilance and Patient Safety, AbbVie, Inc., North Chicago, IL, ¹¹AbbVie B.V., Mijdrecht, Utrecht, Netherlands, ¹²King Abdulaziz University, Jeddah, Saudi Arabia
Background/Purpose: The efficacy and safety of upadacitinib (UPA), an oral reversible Janus kinase inhibitor, have been shown in patients (pts) with moderate/severe RA in the…
Abstract Number: 0440 • ACR Convergence 2023
Baseline T Cell and B Cell-related Markers and HLA-DRB1 Shared Epitope Alleles Predict the Therapeutic Efficacy of Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis
Ting Wang¹, Natalia V. Giltiay², Christian Lood² and Bobby Kwanghoon Han², ¹University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Abatacept, a CTLA-4-Ig fusion protein, is widely used as a treatment for rheumatoid arthritis (RA). However, data on predictive biomarkers associated with therapeutic response…
Abstract Number: 0457 • ACR Convergence 2023
Biologic Disease Modifying Antirheumatic Drug Use in Immune Checkpoint Inhibitor-Treated Cancer Patients with Rheumatoid Arthritis: Utilization and Overall Survival
Deanna Jannat-Khah¹, Jeffrey R Curtis², Fenglong Xie³, Ashish Saxena⁴ and Anne Bass⁵, ¹Hospital For Special Surgery, New York, NY, ²Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

Background/Purpose: There is a dearth of knowledge around the safety of biologic disease modifying antirheumatic drugs (bDMARDS) in immune checkpoint inhibitor (ICI)-treated rheumatoid arthritis (RA)…
Abstract Number: 0736 • ACR Convergence 2023
Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissue Using Large Single-cell Computational Omics
Juan Vargas¹, Ian Mantel², Nirmal Banda¹, Anna Helena Jonsson³, Kevin Wei⁴, Deepak Rao³, Susan Goodman⁵, Kevin Deane¹, The Accelerating Medicines Partnership SLE/RA¹, Jennifer Anolik⁶, Michael Brenner⁴, Soumya Raychaudhuri³, Jennifer Seifert⁷, Michael Holer¹, Laura Donlin⁵ and Fan Zhang⁸, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²Weill Cornell Medicine, New York, NY, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Hospital for Special Surgery, New York, NY, ⁶University of Rochester Medical Center, Rochester, NY, ⁷the Accelerating Medicines Partnership (AMP) RA/SLE Network, Boston, MA, ⁸University of Colorado, Aurora, CO

Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in autoimmune disease pathogenesis. In patients with rheumatoid arthritis…
Abstract Number: 0802 • ACR Convergence 2023
Targeting Fibroblasts in Inflammatory Disease Using Engineered T Cells
Samuel Kemble¹, Christopher Mahony², Charlotte Smith², Joel Rurik³, Haig Aghajanian³, Jonathan Epstein³, Mark Coles⁴ and Adam Croft², ¹University Birmingham, Rugeley, United Kingdom, ²University of Birmingham, Birmingham, United Kingdom, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: Fibroblast activation protein alpha (FAPa) expressing fibroblasts orchestrate tissue inflammation and damage in rheumatoid arthritis (RA) as well as tissue immunity in primary Sjögren's…
Abstract Number: 0972 • ACR Convergence 2023
Increased Incidence of Inflammatory Arthritis After COVID-19 in a Colombian Population
Juan Marin¹, Enrique Mazenett¹, Mauricio Sarmiento¹, Rosalbina Perez¹, Claudia Morales¹, Jorge Dominguez¹, Juan Salazar² and Juan-Manuel Anaya³, ¹Coosalud, EPS, Cartagena, Colombia, ²Universidad Nacional, Medellin, Colombia, ³Coosalud, EPS, Bogotá, Colombia
Background/Purpose: An increase in the incidence of autoimmune diseases after COVID-19 has been reported. Since many diseases exhibit population-specific causal effect sizes, we aimed to…
Abstract Number: 1008 • ACR Convergence 2023
Identifying Inflammatory Arthritis Ambulatory Care Service Model Enhancements Needed to Reduce Avoidable Emergency Department Use
Emilie Pianarosa¹, Pamela Roach¹, Patrick McLane², Meghan Elliott¹, Brian Holroyd³, Shanon McQuitty⁴, Steven Katz³, Nazret Russon², Katie Lin¹, Claire Barber¹ and Cheryl Barnabe¹, ¹University of Calgary, Calgary, AB, Canada, ²Alberta Health Services, Edmonton, AB, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Emergency departments (ED) become a location for non-urgent care when ambulatory care systems are not sufficient. We aim to describe contributing factors to the…
Abstract Number: 1202 • ACR Convergence 2023
Goal Concordant Patient-clinician Dyads Have Higher Odds of Communication Around Rheumatoid Arthritis Goals
Jennifer Barton¹, Danielle ZuZero², Diego Molina Ochoa³, Rachel Matsumoto⁴ and Edward Yelin⁵, ¹VA Portland Health Care System/OHSU, Portland, OR, ²National University of Natural Medicine, Portland, OR, ³University of Maryland School of Medicine, Baltimore, MD, ⁴VA Portland Health Care System, Portland, OR, ⁵University of California San Francisco, San Francisco, CA
Background/Purpose: Goal concordance between patients with chronic disease and their clinicians is linked to improved outcomes, however, less is known about goal concordance and goal…
Abstract Number: 1275 • ACR Convergence 2023
Prevalence of Frailty Among Individuals Living with Rheumatoid Arthritis: A Population-based Cohort Study
Alexandra Legge¹ and Diane Lacaille², ¹Dalhousie University, Halifax, NS, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Studies have demonstrated a link between frailty and chronic inflammation, raising the question of whether chronic inflammatory diseases like rheumatoid arthritis (RA) may be…
Abstract Number: 1291 • ACR Convergence 2023
Risk Factors for Major Adverse Cardiovascular Events and Malignancies in Patients with Rheumatoid Arthritis in a Real-World Setting in Japan
Toshitaka Hirano¹, Naonobu Sugiyama², Masato Hoshi¹, Joo-Young Jo³, Kichul Shin⁴ and Kunihiro Yamaoka⁵, ¹Pfizer Japan Inc, Tokyo, Japan, ²Pfizer Japan Inc, Japan, Japan, ³Pfizer Pharmaceuticals Korea Ltd, Seoul, South Korea, ⁴Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea, ⁵Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Patients (pts) with RA are at an increased risk of major adverse cardiovascular events (MACE) and malignancies vs the general population.1,2 However, risk factors…
Abstract Number: 1307 • ACR Convergence 2023
Impact of Comorbidities on the First bDMARD Effectiveness and Retention Rate After 2 Years of Follow-up in Patients with Rheumatoid Arthritis. Data from the Spanish Registry BIOBADASER
Clementina López Medina¹, Jerusalem Calvo², Lucia Otero-Valera³, Alejandro Escudero Contreras², Rafaela Ortega Castro⁴, Lourdes Ladehesa Pineda⁵, Cristina Campos⁶, Pilar Bernabeu-Gonzálvez⁷, Cristina Bohorquez⁸, Alicia Garcia Dorta⁹, Dolores Ruiz-Montesinos¹⁰, Manuel Enrique Pombo Suarez¹¹, Inmaculada Ros¹², Fernando Alonso³ and Isabel Castrejon¹³, ¹Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ²Reina Sofia University Hospital, Córdoba, Spain, ³Spanish Society of Rheumatology, Madrid, Spain, ⁴Hospital Reina Sofía, Cordoba, Spain, ⁵Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, ⁶Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ⁷General University Hospital Dr. Balmis, Alicante, Spain, ⁸Rheumatology Unit, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ⁹Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁰Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹¹Hospital Clínico Universitario, Santiago de Compostela, Spain, ¹²Rheumatology Department HUSLL, Palma de Mallorca, Spain, ¹³Hospital Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Patients with Rheumatoid Arthritis (RA) have a higher prevalence of comorbidities, compared to the general population. The presence of such comorbidities has been directly…
Abstract Number: 1324 • ACR Convergence 2023
Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK
Roxanne Cooksey¹ and Ernest Choy², ¹Cardiff University, Cardiff, United Kingdom, ²Section of Rheumatology, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Biologic therapy has revolutionised the treatment of rheumatoid arthritis (RA). Randomised control trials have shown that IL-6 inhibitors are superior to adalimumab, a TNF…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].